


Amendments to the Claims

1. (Original) A compound of formula (I)



wherein

R is H;

Ar is an aromatic group selected from unsubstituted phenyl or phenyl substituted with 1, 2, 3, 4 or 5 substituents selected from C₁-C₄ alkyl, O(C₁-C₄ alkyl), S(C₁-C₄ alkyl), halo, and phenyl optionally substituted with halo, C₁-C₄ alkyl or O(C₁-C₄ alkyl);

X is unsubstituted phenyl or phenyl substituted with 1, 2, 3, 4 or 5 substituents selected from C₁-C₄ alkyl, O(C₁-C₄ alkyl), and halo;


R' is H or C₁-C₄ alkyl;

each R¹ is independently H or C₁-C₄ alkyl;

wherein each above-mentioned C₁-C₄ alkyl group is optionally substituted with one or more halo atoms;

or a pharmaceutically acceptable salt thereof.

2. (Original) A compound as claimed in claim 1, represented by formula II:



in which R₂ and R₃ are each independently selected from H, C₁-C₄ alkyl, O(C₁-C₄ alkyl), S(C₁-C₄ alkyl), halo, and phenyl; and

R₄ is selected from H, C₁-C₄ alkyl, O(C₁-C₄ alkyl) and halo;

wherein each above-mentioned C₁-C₄ alkyl group is optionally substituted with one or more halo atoms;
or a pharmaceutically acceptable salt thereof.

3. (Original) A compound as claimed in claim 2, wherein R₂ is selected from C₁-C₂ alkyl, O(C₁-C₂ alkyl), S(C₁-C₂ alkyl), Cl and F wherein each above-mentioned C₁-C₂ alkyl group is optionally substituted with one or more halo atoms.

4. (Original) A compound as claimed in claim 2 or claim 3, wherein R₃ is selected from H, Me and Cl.

5. (Currently amended) A compound as claimed in ~~any one of the claims 2 to claim 4~~, wherein R₄ is selected from H, C₁-C₂ alkyl, O(C₁-C₂ alkyl), Cl and F wherein each above-mentioned C₁-C₂ alkyl group is optionally substituted with one or more halo atoms.

6-9. (Cancelled)

10. (Currently amended) A method for selectively inhibiting the reuptake of serotonin and norepinephrine in mammals, comprising administering to a patient in need thereof an effective amount of a compound as claimed in ~~any one of claims 1-5~~ claim 1 or 2.

11. (Currently amended) A method for treating a disorder associated with serotonin and norepinephrine dysfunction in mammals, comprising administering to a patient in need thereof an effective amount of a compound as claimed in ~~any one of claims 1-5~~ claim 1 or 2.

12. (Currently amended) A method ~~[[or use]]~~ as claimed in ~~any one of claims 8, 9 and claim 11~~, wherein the disorder is selected from depression, OCD, anxiety, memory loss, urinary incontinence, conduct disorders, ADHD, obesity, alcoholism, smoking cessation and pain.

13. (Currently amended) A method ~~[[or use]]~~ as claimed in ~~any one of claims 8, 9 and claim 11~~, wherein the disorder is selected from depression, stress urinary incontinence and pain.

14. (Currently amended) A method ~~[[or use]]~~ as claimed in ~~any one of claims 8, 9 and claim 11~~, wherein the disorder is pain.

15. (Currently amended) A composition comprising a compound as claimed in ~~any one of~~

Docket No. X-15822

~~claims 1-5~~ claim 1 or 2 together with a pharmaceutically acceptable diluent, excipient or carrier.